HTRA3 and gastric cancer: Furthermore, it should be noted that the GC patients with HTRA3-high in M0 subgroup had worse OS and DSS (33.2 vs. 22.7%; P = 0.019; 54.3 vs. 37.2%; P = 0.029), indicating HTRA3 had a greater prognostic role in GC patients without distant metastasis.